Ready to Buy the Dip? Consider This Gene Editing Stock
With its share price off by 11% over the past 12 months, CRISPR Therapeutics (NASDAQ: CRSP) may be down, but it's far from being out. The biotech's efforts to develop gene therapies for conditions like sickle cell disease are continuing, and there's reason to believe that success could be on the horizon. Here's why last year's stock price declines simply won't matter in the long run.